SARASOTA, Fla., Sept. 22, 2005 (PRIMEZONE) -- DNAPrint(tm) genomics, Inc. (OTCBB:DNAG) announced today that President and Chief Executive Officer Richard Gabriel will participate in the Biometrics E-Symposium International Web Conference at 1:00 p.m. Eastern time on Wednesday, September 28.
Mr. Gabriel will make a presentation focusing on the use of eye color testing in the field of forensics. The presentation can be accessed at www.biometrics.e-symposium.com, where it will be archived for one year.
"One of the newest additions to DNAPrint's lineup of forensics technologies is RETINOME(tm), a predictive test for determining individual eye color from a DNA sample," Mr. Gabriel stated. "This is a significant breakthrough for detectives, forensic scientists and medical examiners as it will allow them to develop one additional piece of information during an investigation requiring the latest forensics tools."
The symposium is being jointly sponsored by the International Association of Biometrics, based in Northampton, U.K.; the European Biometrics Forum based in Dublin, Ireland; the International Biometric Industry Association, based in Washington, D.C.; and the Biometrics Institute based in Artamon, Australia,
About DNAPrint genomics, Inc.
DNAPrint genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services focused on drug development, pharmacogenomic diagnostic tests, forensics technology and consumer genetic tests. DNAPrint's family of products for the law enforcement forensics and consumer markets include DNAWITNESS(tm), RETINOME(tm), ANCESTRYbyDNA(tm) and EURO-DNA(tm).
Safe Harbor Provision
All statements in this press release that are not historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act as amended. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.